Skip to content

TKR With and Without the Use of Intra-operative Sensing

Randomized Controlled Trial of Patients Undergoing a Total Knee Arthroplasty With and Without the Use of Intraoperative Sensing Technology

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04251442
Enrollment
0
Registered
2020-02-05
Start date
2019-10-31
Completion date
2020-10-30
Last updated
2022-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Osteoarthritis, Total knee repalcement

Brief summary

The purpose of this study is to determine if there is a difference in clinical outcomes after total knee replacement (TKR) performed with traditional ligament balancing compared to use of intraoperative sensing technology (IOS) to balance ligaments. IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants. A total of 150 subjects will participate in this study at Hospital for Special Surgery. The hypotheses are that the use of IOS technology will be associated with: 1. Better soft tissue balance during TKR than by manual balancing alone. 2. Higher patient reported clinical outcome measures (PROMs) following surgery.

Detailed description

Participation in this study will involve a knee replacement performed with IOS. Patients will be randomized into one of two groups:The study group will have soft tissue balance performed with the use of IOS. Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values. Intra-operative compartment loads will be measured in 10, 45, and 90 degrees of flexion. Additionally, long leg limb alignment, passive range of motion, use of opioids, daily activity, and PROMS will be evaluated post-operatively to determine which group has better outcomes.

Interventions

DEVICEOrthoSensor Verasense Technology

IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.

Sponsors

Orthosensor, Inc.
CollaboratorINDUSTRY
Hospital for Special Surgery, New York
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients who meet the indications for use for primary TKR using IOS * Subject must be diagnosed with osteoarthritis * Subject is likely to be available for all study visits * Subject is able and willing to sign the informed consent and follow study procedures

Exclusion criteria

* Revision total knee arthroplasty * Patient is receiving treatment for any of the following conditions: 1. Avascular Necrosis 2. Inflammatory arthritis 3. Post-traumatic arthritis * Any knee surgery other than meniscectomy (can be arthroscopic or open) * Ligament insufficiencies, prior surgeries such as anterior cruciate ligament (ACL) or posterior cruciate ligament (PCL) reconstructions, posterolateral reconstructions, osteotomies, tibia plateau fractures * Ipsilateral foot/ankle and hip arthritis * Range of motion less than 90° * Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e. severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease) * Any subjects meeting any contraindication criteria as identified in the locally approved labeling for the device should be excluded from this study. * Patient out-of-state with medication prescription not registered in iStop database * Patients with severe contralateral osteoarthritis requiring subsequent knee replacement or with a flexion contracture greater than 10 degrees.

Design outcomes

Primary

MeasureTime frameDescription
Knee Society Score4 monthsThe primary outcome will be the difference in Knee Society Score (KSS) between baseline and 4 months post-operatively. The Knee Society Score is out of 100 points, with a higher score meaning a patient had a better outcome.

Secondary

MeasureTime frameDescription
Long Leg Limb Alignment6 weeksLong leg limb alignment will be measured on post-operative standard of care (SOC) radiographs at patients' 6 week follow-ups.
Passive Range of Motion4 monthsPassive range of motion will be measured pre-operatively, 6 weeks post-operatively, and 4 months post-operatively at all scheduled SOC appointments.
Intra-operative Compartment LoadsIntra-operativeIntra-operative compartment loads (medial and lateral component loads) will be measured between the groups at 10, 45, and 90 degrees of flexion during trial reduction and after cementation, using IOS technology.
Function and Activity6 weeksFunction and activity will be monitored using Fitness Trackers. The device will be given to each patient in hospital and is to be worn for 6 weeks post-operatively. It will monitor a patient's daily and weekly steps while the patient is wearing it.
Pain Level6 weeksDaily pain levels will also be measured using the fitness tracker. The tracker will ask the patient to rate their pain on a scale from 0-10, with 0 meaning they have no pain, and 10 being the worst pain imaginable.
Opioid Use6 weeksUse of opioids will be tracked using the Internet System for Tracking Over Prescribing (I-STOP) database and a daily pain diary maintained by patient for first 6 weeks post-operatively. The I-STOP database can be accessed by the prescribing physician to track how many opioid refills a patient has procured.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026